Asset
Ulefnersen
Ionis Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04768972 | phase3 | active_not_recruiting | 2021-06-14 | 2026-06-17 | Ionis Pharmaceuticals, Inc. | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) |
FDA applications (0)
This company has no applications containing this asset.